Eran Orr: Using Virtual Reality to Treat ADHD Patients

Video

The younger generation is able to adapt to new technology for therapy better than previous generations.

With the ongoing coronavirus disease 2019 (COVID-19) pandemic raging on, there is a need for in-home therapy tools for children with attention-deficit hyperactivity disorder (ADHD).

One area where that can be achieved is through virtual reality platforms. While VR likely won’t be able to replace the cancelled sports and social events, it does offer an immersive social experience with a therapeutic arm.

XRHealth recently unveiled a new ADHD virtual reality platform with the goal of improving well-known ADHD cognitive functioning, including attention, impulsivity, and higher and more complex thinking functions such as initiating, organizing, planning, and fully executing daily tasks.

The new system is based on the brain’s ability to restructure itself in attempt to overcome existing challenges, referred to as the brain’s plasticity principle.

Doctors are able to monitor each user for progress biased on sustained focus in the face of distractions.

In an interview with HCPLive®, Evan Orr, Founder and CEO of XRHealth, explained how the virtually reality can be a crucial tool for ADHD patients, particularly during the ongoing pandemic where many are forced home from school, but still unable to go to therapy.

Orr said the use of virtual reality is beneficial because younger ADHD patients are already familiar and comfortable with some of the technology used for the platform.

Related Videos
Sejal Shah, MD | Credit: Brigham and Women's
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
© 2024 MJH Life Sciences

All rights reserved.